HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vitamin D Supplements And COVID-19: Still No Evidence, No Harm In Doing It Anyway

Executive Summary

Two new RCTs cast further doubt on the preventative effects of vitamin D supplementation with regards to COVID-19 infection. Nevertheless, an editorial in the British Medical Journal, where the studies were published, leaves open positive effects for those suffering from vitamin D deficiency, and recommends a daily supplement of up to 2000IU just in case.

You may also be interested in...

Industry Suggests NIH Office Of Dietary Supplements Get More Current, Collaborative

Industry comments on NIH ODS strategic plan focus on persuading it to give trade associations input on its activities, specifically for fact sheets on dietary supplement topics. Stakeholders also want more dialogue with ODS and opportunity to comment on initiatives.

No OTC High Dose Vit D3 Supplements, Say German Doctors After Infant Overdose Case

The Drug Commission of the German Medical Association warns against the unsupervised use of high-dose vitamin D3 supplements after the overdose of a seven-month-old German infant.

UK Vitamin D Overdose Case Not Reflective Of Ordinary Use, Says Industry

A recent case of overdose linked to use of vitamin D supplements is not reflective of how consumers ordinarily use these products, say the UK’s Health and Food Supplements Information Service and Health Food Manufacturer's Association.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts